STOCK TITAN

Nexalin Technology, Inc. Warrant - NXLIW STOCK NEWS

Welcome to our dedicated page for Nexalin Technology Warrant news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology Warrant stock.

Nexalin Technology Inc. offers a drug-free therapy for anxiety, depression, and insomnia. The patented waveform of the Nexalin device provides transcranial electrical stimulation, resulting in increased beta-endorphins and balance in the brain's neurochemistry.

The FDA-approved Gen-1 device uses bioelectronic medical technology to treat anxiety and insomnia without drugs. Nexalin's neurostimulation products aim to combat the global mental health epidemic with safe and effective solutions.

The company's innovative Gen-3 HALO™ Clarity Virtual Clinic model and growing clinical data support the efficacy of its therapy. With extensive safety analysis and FDA approval, Nexalin is a leader in non-invasive mental health treatment.

Rhea-AI Summary
Nexalin Technology reports positive results in migraine and depression clinical studies, indicating potential therapeutic benefits of its neurostimulation device. The migraine study showed a significant reduction in pain frequency and degree, with a strong safety profile. The depression study demonstrated better remission and response rates compared to sham treatment. Mental health conditions are increasing globally. The migraine and depression markets are estimated at $3.9 billion and $11.2 billion, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
-
Rhea-AI Summary
Nexalin Technology, Inc. announced that its CEO, Mark White, will be participating in a live interview with the 'Big Biz Show' to discuss recent developments and upcoming milestones regarding their non-invasive, frequency-based, deep-brain stimulation medical devices for treating mental health and addiction disorders. The interview will be aired on cable TV, streaming services, and radio in 175 countries, with podcasts available on various platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
-
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) announced the formation of 'Nexalin America' to collaborate with U.S. government agencies for the use of its non-invasive deep-brain stimulation devices in treating PTSD, traumatic brain injury, anxiety, depression, and insomnia. The company has hired industry and government affairs veteran, Ryan Kane, to lead this initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none
Rhea-AI Summary
Nexalin Technology, Inc. announces that their abstract on traumatic brain injury (TBI) has been accepted for presentation at the 2023 Military Health System Research Symposium. The abstract describes a study using MEG to assess neuronal changes in veterans with combat-related mTBI after treatment with Nexalin's non-invasive deep-brain stimulation device. The reduction of hyperactivity in mTBI suggests the treatment can be effective without side effects. The study builds on prior data in insomnia, which has shown a high correlation with TBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary
Nexalin Technology has formed a joint venture with Wider Come Limited to develop and distribute its second generation transcranial Alternating Current Stimulation (tACS) devices in China and the Asia Pacific region. Wider will also fund and conduct four clinical trials using Nexalin's devices for the treatment of insomnia, depression, and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
none
-
Rhea-AI Summary

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.06%
Tags
none
Rhea-AI Summary

Nexalin Technology announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical, and Regulatory. Nketiah brings over 23 years of experience in regulatory affairs and clinical operations, specifically with the FDA. His expertise will support the company in accelerating FDA clearance for its Generation 2 and Generation 3 neurostimulation devices, aimed at improving healthcare outcomes for mental and neurodegenerative illnesses. The Gen-2 device is designed to penetrate deeper into the brain using an advanced waveform, while the Gen-3 prototype will utilize a virtual-clinic model for treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
management
-
Rhea-AI Summary

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update emphasizing its advancements in neurostimulation devices aimed at combating mental health disorders. The company is enhancing its Gen-1 device to a more powerful Gen-2 model with a waveform increase from 4 milliamps to 15 milliamps, expected to improve treatment efficacy. Plans for FDA submissions and clinical trials are outlined, including a strategy for addressing Major Depressive Disorder. Additionally, Nexalin reports progress with its devices in China and a recent white paper supporting its technology's effectiveness for anxiety treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary

Nexalin Technology, Inc. (NXL, NXLIW) announced positive results from a white paper published by the Second Xiangya Hospital, documenting the effectiveness of its tACS device for treating generalized anxiety disorder. The study reported complete disappearance of somatic anxiety symptoms and improved sleep quality in a patient after a 10-day treatment regimen. The benefits persisted for four months, indicating the device's potential in addressing mental health issues without side effects. The company aims to expand its clinical research and treatment applications in the mental health field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
Rhea-AI Summary

Nexalin Technology, Inc. has successfully closed its initial public offering of 2,315,000 units, each unit comprising one share of common stock and one warrant, at an offering price of $4.15 per unit. This translates to gross proceeds of approximately $9.6 million before expenses. Trading commenced on The Nasdaq Capital Market under the symbols ‘NXL’ for shares and ‘NXLIW’ for warrants on September 16, 2022. The company has also granted underwriters a 45-day overallotment option for additional securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags

FAQ

What is the current stock price of Nexalin Technology Warrant (NXLIW)?

The current stock price of Nexalin Technology Warrant (NXLIW) is $0.2 as of November 5, 2024.

What does Nexalin Technology Inc. offer?

Nexalin provides a drug-free therapy for anxiety, depression, and insomnia using bioelectronic medical technology.

What is the patented waveform technology of the Nexalin device?

The patented waveform provides transcranial electrical stimulation, resulting in increased beta-endorphins and balance in the brain's neurochemistry.

How does the Gen-1 device work?

The Gen-1 device uses bioelectronic medical technology to treat anxiety and insomnia without the need for drugs.

What is the Gen-3 HALO™ Clarity Virtual Clinic model?

The Gen-3 HALO™ Clarity Virtual Clinic model is an innovative approach to providing therapy and support for mental health issues.

Is Nexalin FDA-approved?

Yes, Nexalin has undergone extensive safety analysis and FDA approval for its therapy devices.

What makes Nexalin a leader in mental health treatment?

Nexalin's focus on safe, non-invasive, and effective therapy solutions positions them as leaders in combating the global mental health epidemic.

What clinical data supports Nexalin's therapy?

Growing clinical data supports the efficacy of Nexalin's neurostimulation technology in treating mental health disorders.

How does Nexalin's therapy differ from traditional treatments?

Nexalin's therapy offers a drug-free, non-invasive approach to treating anxiety, depression, and insomnia, without the need for psychotherapy.

Where can I learn more about Nexalin Technology Inc.?

For additional information about Nexalin Technology Inc., visit their official website at https://nexalin.com/.

Nexalin Technology, Inc. Warrant

Nasdaq:NXLIW

NXLIW Rankings

NXLIW Stock Data

7.59M
Medical Devices
Healthcare
Link
United States of America
Houston